Nasal Spray Medicine For Treatment-Resistant Depression Not Recommended By NICE

The National Institute for Health and Care Excellence (NICE) announced that esketamine, a nasal spray for treatment-resistant depression, has not been recommended by NICE because of uncertainties over its clinical and cost effectiveness. As a result, esketamine (also called Spravato and made by Janssen) combined with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor is not recommended, within its marketing authorization, for adults with treatment-resistant depression that have not responded to at least two different antidepressants in the current moderate to severe depressive episode.

Esketamine is given as a nasal spray, supervised by a health care . . .